Atara Biotherapeutics (NASDAQ:ATRA)‘s stock had its “buy” rating reiterated by equities research analysts at William Blair in a research note issued on Thursday, TipRanks reports.
Several other research firms have also weighed in on ATRA. ValuEngine lowered shares of Atara Biotherapeutics from a “buy” rating to a “hold” rating in a research note on Friday. Cowen reissued a “buy” rating on shares of Atara Biotherapeutics in a research note on Tuesday, February 26th. BidaskClub lowered shares of Atara Biotherapeutics from a “buy” rating to a “hold” rating in a research note on Friday, February 22nd. Zacks Investment Research raised shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, April 30th. Finally, Mizuho started coverage on shares of Atara Biotherapeutics in a research note on Tuesday, January 22nd. They set a “buy” rating and a $62.00 price objective on the stock. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $43.33.
Shares of NASDAQ ATRA traded down $0.18 during mid-day trading on Thursday, hitting $23.99. The company’s stock had a trading volume of 429,600 shares, compared to its average volume of 560,288. The firm has a market capitalization of $1.15 billion, a PE ratio of -4.55 and a beta of 2.11. The company has a current ratio of 9.96, a quick ratio of 9.96 and a debt-to-equity ratio of 0.05. Atara Biotherapeutics has a one year low of $23.58 and a one year high of $54.45.
Atara Biotherapeutics (NASDAQ:ATRA) last issued its earnings results on Thursday, May 9th. The biotechnology company reported ($1.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.48) by $0.04. As a group, equities research analysts anticipate that Atara Biotherapeutics will post -5.69 earnings per share for the current fiscal year.
In other Atara Biotherapeutics news, insider Joe Newell sold 1,500 shares of Atara Biotherapeutics stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $36.13, for a total value of $54,195.00. Following the transaction, the insider now owns 48,646 shares of the company’s stock, valued at $1,757,579.98. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Isaac E. Ciechanover sold 7,800 shares of Atara Biotherapeutics stock in a transaction that occurred on Thursday, February 28th. The shares were sold at an average price of $36.14, for a total transaction of $281,892.00. Following the completion of the transaction, the chief executive officer now directly owns 332,243 shares in the company, valued at approximately $12,007,262.02. The disclosure for this sale can be found here. Insiders have sold a total of 129,990 shares of company stock worth $4,678,666 in the last three months. 10.60% of the stock is owned by insiders.
Institutional investors and hedge funds have recently made changes to their positions in the business. Manchester Capital Management LLC bought a new position in Atara Biotherapeutics in the first quarter valued at approximately $56,000. Quantamental Technologies LLC bought a new position in Atara Biotherapeutics in the fourth quarter valued at approximately $62,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its stake in Atara Biotherapeutics by 31.7% in the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 4,042 shares of the biotechnology company’s stock valued at $115,000 after buying an additional 974 shares in the last quarter. Meeder Asset Management Inc. bought a new position in Atara Biotherapeutics in the fourth quarter valued at approximately $128,000. Finally, Coastal Investment Advisors Inc. bought a new position in Atara Biotherapeutics in the first quarter valued at approximately $142,000.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.
Recommended Story: Compound Interest and Why It Matters When Investing
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.